Aβ Oligomers -: a decade of discovery

被引:1597
作者
Walsh, Dominic M. [1 ]
Selkoe, Dennis J.
机构
[1] Univ Coll Dublin, Lab Neurodegenerat Res, Conway Inst, Dublin 4, Ireland
[2] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA
基金
英国惠康基金;
关键词
aggregation; Alzheimer's disease; amyloid beta-protein; oligomerization; synaptic dysfunction;
D O I
10.1111/j.1471-4159.2006.04426.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Converging lines of evidence suggest that progressive accumulation of the amyloid beta-protein (A beta) plays a central role in the genesis of Alzheimer's disease, but it was long assumed that A beta had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. Over the past decade, data have emerged from the use of synthetic A beta peptides, cell culture models, beta-amyloid precursor protein transgenic mice and human brain to suggest that pre-fibrillar, diffusible assemblies of A beta are also deleterious. Although the precise molecular identity of these soluble toxins remains unsettled, accumulating evidence suggests that soluble forms of A beta are indeed the proximate effectors of synapse loss and neuronal injury. Here we review recent progress in understanding the role of soluble oligomers in Alzheimer's disease.
引用
收藏
页码:1172 / 1184
页数:13
相关论文
共 146 条
[131]   The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain [J].
Walsh, DM ;
Tseng, BP ;
Rydel, RE ;
Podlisny, MB ;
Selkoe, DJ .
BIOCHEMISTRY, 2000, 39 (35) :10831-10839
[132]  
Walsh Dominic M., 2003, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V3, P277, DOI 10.2174/1568013033483311
[133]   Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus [J].
Wang, HW ;
Pasternak, JF ;
Kuo, H ;
Ristic, H ;
Lambert, MP ;
Chromy, B ;
Viola, KL ;
Klein, WL ;
Stine, WB ;
Krafft, GA ;
Trommer, BL .
BRAIN RESEARCH, 2002, 924 (02) :133-140
[134]   The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging [J].
Wang, J ;
Dickson, DW ;
Trojanowski, JQ ;
Lee, VMY .
EXPERIMENTAL NEUROLOGY, 1999, 158 (02) :328-337
[135]   IDENTIFICATION, BIOGENESIS, AND LOCALIZATION OF PRECURSORS OF ALZHEIMERS-DISEASE A4 AMYLOID PROTEIN [J].
WEIDEMANN, A ;
KONIG, G ;
BUNKE, D ;
FISCHER, P ;
SALBAUM, JM ;
MASTERS, CL ;
BEYREUTHER, K .
CELL, 1989, 57 (01) :115-126
[136]   A novel ε-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with notch processing [J].
Weidemann, A ;
Eggert, S ;
Reinhard, FBM ;
Vogel, M ;
Paliga, K ;
Baier, G ;
Masters, CL ;
Beyreuther, K ;
Evin, G .
BIOCHEMISTRY, 2002, 41 (08) :2825-2835
[137]   The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease [J].
Westerman, MA ;
Cooper-Blacketer, D ;
Mariash, A ;
Kotilinek, L ;
Kawarabayashi, T ;
Younkin, LH ;
Carlson, GA ;
Younkin, SG ;
Ashe, KH .
JOURNAL OF NEUROSCIENCE, 2002, 22 (05) :1858-1867
[138]   Small non-fibrillar assemblies of amyloid β-protein bearing the Arctic mutation induce rapid neuritic degeneration [J].
Whalen, BM ;
Selkoe, DJ ;
Hartley, DM .
NEUROBIOLOGY OF DISEASE, 2005, 20 (02) :254-266
[139]   Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice [J].
White, AR ;
Reyes, R ;
Mercer, JFB ;
Camakaris, J ;
Zheng, H ;
Bush, AI ;
Multhaup, G ;
Beyreuther, K ;
Masters, CL ;
Cappai, R .
BRAIN RESEARCH, 1999, 842 (02) :439-444
[140]   PEPTIDES HOMOLOGOUS TO THE AMYLOID PROTEIN OF ALZHEIMERS-DISEASE CONTAINING A GLUTAMINE FOR GLUTAMIC-ACID SUBSTITUTION HAVE ACCELERATED AMYLOID FIBRIL FORMATION [J].
WISNIEWSKI, T ;
GHISO, J ;
FRANGIONE, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 179 (03) :1247-1254